Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation

American Journal of Hematology

Volumn 91, Issue 10, 2016, Pages 984-988

  Hwa, Yi L ^a   Kumar, Shaji K ^a   Gertz, Morie A ^a   Lacy, Martha Q ^a   Buadi, Francis K ^a   Kourelis, Taxiarchis V ^a   Gonsalves, Wilson I ^a   Rajkumar, S Vincent ^a   Go, Ronald S ^a   Leung, Nelson ^a   Kapoor, Prashant ^a   Dingli, David ^a   Kyle, Robert A ^a   Russell, Stephen ^a   lust, John A ^a   Hayman, Suzanne R ^a   Lin, Yi ^a   Zeldenrust, Steven ^a   Dispenzieri, Angela ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLASMACYTOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TRANSPLANTATION CONDITIONING;

EID: 84990205097     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24453     Document Type: Article

References (35)

1. Merlini G, Seldin DC, Gertz MA. Amyloidosis: Pathogenesis and new therapeutic options. J Clin Oncol 2011;29:1924–1933.
2. Skinner M, Anderson J, Simms R, et al. Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996;100:290–298.
3. Kyle RA, Greipp PR. Primary systemic amyloidosis: Comparison of melphalan and prednisone versus placebo. Blood 1978;52:818–827.
4. Kyle RA, Greipp PR, Garton JP, et al. Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine. Am J Med 1985;79:708–716.
5. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336:1202–1207.
6. Sher T, Hayman SR, Gertz MA. Treatment of primary systemic amyloidosis (AL): Role of intensive and standard therapy. Clin Adv Hematol Oncol: H&O 2012;10:644–651.
7. Gertz MA. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. Am J Hematol 2014;89:1132–1140.
8. Gertz MA, Lacy MQ, Dispenzieri A, et al. Transplantation for amyloidosis. Curr Opin Oncol 2007;19:136–141.
9. Sanchorawala V, Seldin DC. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis. Amyloid 2007;14:261–269.
10. Kumar S, Dispenzieri A, Gertz MA. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2008; 358:91 author reply 92–93.
11. Gertz MA, Lacy MQ, Dispenzieri A, et al. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: A status report. Leuk Lymphoma 2010;51:2181–2187.
12. Weber N, Mollee P, Augustson B, et al. Management of systemic AL amyloidosis: Recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Intern Med J 2015;45:371–382.
13. Gertz M, Lacy M, Dispenzieri A, et al. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma 2008;36–41.
14. Jimenez-Zepeda VH, Franke N, Reece DE, et al. Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: Experience of a single institution. Br J Haematol 2014;164:722–728.
15. Gertz MA, Lacy MQ, Dispenzieri A, et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: Importance of achieving a complete response. Haematologica 2007;92:1415–1418.
16. Dispenzieri A, Seenithamby K, Lacy MQ, et al. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: A retrospective review from a tertiary referral center. Bone Marrow Transplant 2013;48:1302–1307.
17. Cibeira MT, Sanchorawala V, Seldin DC, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: Long-term results in a series of 421 patients. Blood 2011;118:4346–4352.
18. Kyle RA, Gertz MA. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45–59.
19. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989–995.
20. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac Troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751–3757.
21. Kourelis TV, Kumar SK, Gertz MA, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol 2013;31:4319–4324.
22. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79:319–328.
23. Rajkumar SV, Fonseca R, Dispenzieri A, et al. Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation. Am J Hematol 2001;68:269–275.
24. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes. J Clin Oncol 2012;30:4541–4549.
25. Huang X, Wang Q, Chen W, et al. Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: A randomized controlled trial. BMC Med 2014;12:2
26. Sanchorawala V, Brauneis D, Shelton AC, et al. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial. Biol Blood Marrow Transplant 2015;21:1445–1451.
27. Scott EC, Heitner SB, Dibb W, et al. Induction bortezomib in AL amyloidosis followed by high dose melphalan and autologous stem cell transplantation: A single institution retrospective study. Clin Lymphoma Myeloma Leuk 2014;14:424–430. e421.
28. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012;119:4391–4394.
29. Kumar SK, Dingli D, Dispenzieri A, et al. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT. Bone Marrow Transplant 2008;41:1013–1019.
30. Lahuerta JJ, Mateos MV, Martinez-Lopez J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: Sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008;26:5775–5782.
31. Landau H, Hassoun H, Rosenzweig MA, et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia 2013;27:823–828.
32. Cohen AD, Zhou P, Chou J, et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: Results of a phase II trial. Br J Haematol 2007;139:224–233.
33. Sanchorawala V, Wright DG, Seldin DC, et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: Results of a prospective randomized trial. Bone Marrow Transplant 2004;33:381–388.
34. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007;109:465–470.
35. Palladini G, Merlini G. Uniform risk-stratification and response criteria are paving the way to evidence-based treatment of AL amyloidosis. Oncology 2011;25:633, 637–638.